Effect on adherence to nicotine replacement therapy of informing smokers their dose is determined by their genotype: A randomised controlled trial

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Marteau, Theresa M ^a   Aveyard, Paul ^b   Munafò, Marcus R ^c   Prevost, A Toby ^a   Hollands, Gareth J ^a   Armstrong, David ^a   Sutton, Stephen ^d   Hill, Chloe ^a   Johnstone, Elaine ^e   Kinmonth, Ann Louise ^d  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; MU OPIATE RECEPTOR; NICOTINE; NICOTINE GUM; NICOTINE LOZENGE; NICOTINE PATCH; OPRM1 PROTEIN, HUMAN;

ADULT; ARTICLE; BEHAVIOR; CONFIDENCE INTERVAL; CONTROLLED STUDY; DNA DETERMINATION; FEMALE; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HYPOTHESIS; MAJOR CLINICAL STUDY; MALE; MOTIVATION; NICOTINE REPLACEMENT THERAPY; OPEN STUDY; OUTPATIENT DEPARTMENT; PARALLEL DESIGN; PATIENT COMPLIANCE; PHENOTYPE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SMOKING; TOBACCO DEPENDENCE; TRANSDERMAL PATCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; GENETICS; MIDDLE AGED; PSYCHOLOGICAL ASPECT; SMOKING CESSATION;

ADULT; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NICOTINE; QUESTIONNAIRES; RECEPTORS, OPIOID, MU; SMOKING CESSATION; TOBACCO USE CESSATION PRODUCTS; TOBACCO USE DISORDER;

EID: 84859616920     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0035249     Document Type: Article

References (33)

1. Li MD, (2006) The genetics of nicotine dependence. Curr Psychiatry Rep 8: 158-164.
2. Li MD, Cheng R, Ma JZ, Swan GE, (2003) A meta-analysis of estimated genetic and environmental effects on smoking behavior in male and female adult twins. Addiction 98: 23-31.
3. Schnoll RA, Johnson TA, Lerman C, (2007) Genetics and smoking behavior. Curr Psychiatry Rep 9: 349-357.
4. Lerman CE, Schnoll RA, Munafo MR, (2007) Genetics and smoking cessation- Improving outcomes in smokers at risk. American Journal of Preventive Medicine 33: S398-S405.
5. Munafò MR, Lerman C, Niaura R, Shields AE, Swan GE, (2005) Smoking cessation treatment: Pharmacogenetic assessment. Current Opinion in Molecular Therapeutics 7: 202-208.
6. Munafò MR, Shields AE, Berrettini W, Patterson F, Lerman C, (2005) Pharmacogenetics and nicotine addiction treatment. Pharmacogenomics 6: 211-223.
7. Lerman C, Wileyto EP, Patterson F, Rukstalis M, Audrain-McGovern J, et al. (2004) The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial. Pharmacogenomics Journal 4: 184-192.
8. Munafo MR, Elliot KM, Murphy MF, Walton RT, Johnstone EC, (2007) Association of the mu-opioid receptor gene with smoking cessation. Pharmacogenomics J 7: 353-361.
9. Collins F, Green E, Guttmacher A, Guyer M, (2003) A vision for the future of genomics research: a blueprint for the genomic future. Nature 422: 835-847.
10. Gramling R, Nash J, Siren K, Culpepper L, (2003) Predictive genetics in primary care: expectations for the motivational impact of genetic testing affects the importance family physicians place on screening for familial cancer risk. Genetics in Medicine 5: 172-175.
11. Collins F, (2010) Has the revolution arrived? Nature 464: 674-675.
12. Chen S, Chaiken S, Trope Y, (1999) The heuristic-systematic model in its broader context. Dual process theories in social psychology. New York Guilford Press pp. 73-96.
13. Marteau TM, Weinman J, (2006) Self-regulation and the behavioural response to DNA risk information: A theoretical analysis and framework for future research. Social Science & Medicine 62: 1360-1368.
14. Iselin MG, Addis ME, (2003) Effects of etiology on perceived helpfulness of treatments for depression. Cognitive Therapy and Research 27: 205-222.
15. Marteau T, Senior V, Humphries SE, (2004) Psychological impact of genetic testing for familial hypercholesterolemia within a previously aware population: A randomized controlled trial. Am J Med Genet 128A: 285-293.
16. Phelan JC, Yang LH, Cruz-Rojas R, (2006) Effects of attributing serious mental illnesses to genetic causes on orientations to treatment. Psychiatric Services 57: 382-387.
17. Wright AJ, Weinman J, Marteau TM, (2003) The impact of learning of a genetic predisposition to nicotine dependence: an analogue study. Tobacco Control 12: 227-230.
18. Wu JR, Moser DK, Lennie TA, Burkhart PV, (2008) Medication adherence in patients who have heart failure: a review of the literature. Nursing Clinics of North America 43: 133-153.
19. Shiffman S, (2007) Use of more nicotine lozenges leads to better success in quitting smoking. Addiction 102: 809-814.
20. Shiffman S, (2008) Effect of nicotine lozenges on affective smoking withdrawal symptoms: Secondary analysis of a randomized, double-blind, placebo-controlled clinical trial. Clinical Therapeutics 30: 1461-1475.
21. Shiloh S, Rashuk-Rosenthal D, Benyamini Y, (2002) Illness causal attributions: An exploratory study of their structure and associations with other illness cognitions and perceptions of control. Journal of Behavioral Medicine 25: 373-394.
22. Collins RE, Wright AJ, Marteau TM, (2011) Impact of communicating personalized genetic risk information on perceived control over the risk: A systematic review. Genetics in Medicine 13: 273-277.
23. Hajek P, (1989) Withdrawal-oriented therapy for smokers. British Journal of Addiction 84: 591-598.
24. NCSCT (NHS Centre for Smoking Cessation and Training) (2010) Learning Outcomes for Training Stop Smoking Specialists. London NCSCT.
25. Stead LF, Perera R, Bullen C, Mant D, Lancaster T, (2008) Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev.
26. Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom K-O, (1991) The Fagerström Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. British Journal of Addiction 86: 1119-1127.
27. Marteau T, Munafo M, Aveyard P, Hill C, Whitwell S, et al. (2010) Trial Protocol: Using genotype to tailor prescribing of nicotine replacement therapy: a randomised controlled trial assessing impact of communication upon adherence. BMC Public Health 10: 680.
28. West R, Hajek P, Stead L, Stapleton J, (2005) Outcome criteria in smoking cessation trials: proposal for a common standard. Addiction 100: 299-303.
29. Marteau TM, Bekker H, (1992) The development of a six-item short form of the state scale of the Speilberger state trait anxiety inventory. British Journal of Clinical Psychology 31: 301-306.
30. Alterman AI, Gariti P, Cook TG, Cnaan A, (1999) Nicodermal patch adherence and its correlates. Drug & Alcohol Dependence 53: 159-165.
31. Lancaster GA, Campbell MJ, Eldridge S, Farrin A, Marchant M, et al. (2010) Trials in primary care: statistical issues in the design, conduct and evaluation of complex interventions. Statistical Methods in Medical Research 19: 349-377.
32. Webb TL, Sheeran P, (2006) Does changing behavioral intentions engender bahaviour change? A meta-analysis of the experimental evidence. Psychological Bulletin 132: 249-268.
33. Marteau TM, French DP, Griffin SJ, Prevost AT, Sutton S, et al. (2010) Effects of communicating DNA-based disease risk estimates on risk-reducing behaviours. Cochrane Database Syst Rev CD007275.